About
Titles
Director Internal Medicine Cardiology
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Louise Gambone's published research.
Publications Timeline
A big-picture view of Louise Gambone's research output by year.
Alexandra Lansky, MD, FACC, FAHA, FESC
Helen Parise, ScD
Cody Pietras
John K Forrest, MD, FACC, FSCAI
James V. Freeman, MD, MPH, MS
Jeptha Curtis, MD
12Publications
596Citations
Publications
2024
PREDICTORS AND CONSEQUENCES OF BRAIN INJURY VOLUME BY DIFFUSION-WEIGHTED MRI FOLLOWING TAVR
Grubman D, Dwyer M, Lansky A, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Parise H, Messe S. PREDICTORS AND CONSEQUENCES OF BRAIN INJURY VOLUME BY DIFFUSION-WEIGHTED MRI FOLLOWING TAVR. Journal Of The American College Of Cardiology 2024, 83: 970. DOI: 10.1016/s0735-1097(24)02960-7.Peer-Reviewed Original Research800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis
Grubman D, Lansky A, Dwyer M, Zivadinov R, Pietras C, Nazif T, Moses J, Shah T, Gambone L, Leon M, Forrest J, Vora A, Parise H, Messé S. 800.09 Surgical Risk Does Not Predict Ischemic Stroke or Acute Infarction After TAVR: Results of a Patient-Level Pooled Analysis. JACC Cardiovascular Interventions 2024, 17: s67-s68. DOI: 10.1016/j.jcin.2024.01.234.Peer-Reviewed Original Research
2022
Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry
Friedman DJ, Pierre D, Wang Y, Gambone L, Koutras C, Segawa C, Farb A, Vemulapalli S, Varosy PD, Masoudi FA, Lansky A, Curtis JP, Freeman JV. Development and validation of an automated algorithm for end point adjudication for a large U.S. national registry. American Heart Journal 2022, 254: 102-111. PMID: 36007567, DOI: 10.1016/j.ahj.2022.08.006.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsEnd point adjudicationCEC adjudicationEnd pointLarge registriesClinical trialsNational Cardiovascular Data RegistryMajor vascular complicationsU.S. National RegistryPost-discharge eventsAgreement rateMajor bleedingNeurologic eventsVascular complicationsNational registryEvent adjudicationData registryRegistryCommittee's evaluationsPercent agreementGold standardAgreement thresholdHospitalTrialsFurther confirmationBleeding
2018
TCT-432 FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-up Clinical Outcomes Final Results
Bouras G, Abizaid A, Lutz M, Carrie D, Weber-Albers J, Dudek D, Gambone L, Anderson J, Lansky A. TCT-432 FANTOM II trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – 24-Month Follow-up Clinical Outcomes Final Results. Journal Of The American College Of Cardiology 2018, 72: b174. DOI: 10.1016/j.jacc.2018.08.1597.Peer-Reviewed Original ResearchCitationsConcepts
2015
Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study.
Baumbach A, Mullen M, Brickman AM, Aggarwal SK, Pietras CG, Forrest JK, Hildick-Smith D, Meller SM, Gambone L, den Heijer P, Margolis P, Voros S, Lansky AJ. Safety and performance of a novel embolic deflection device in patients undergoing transcatheter aortic valve replacement: results from the DEFLECT I study. EuroIntervention 2015, 11: 75-84. PMID: 25868876, DOI: 10.4244/eijy15m04_01.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAgedAged, 80 and overAlloysAortic ValveAortic Valve StenosisBrain IschemiaBrazilCardiac CatheterizationCognitionCognition DisordersDiffusion Magnetic Resonance ImagingEmbolic Protection DevicesEuropeFemaleHeart Valve ProsthesisHeart Valve Prosthesis ImplantationHumansIntracranial EmbolismMalePredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSeverity of Illness IndexStrokeTime FactorsTreatment OutcomeUltrasonography, Doppler, TranscranialConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementNew cerebral ischemic lesionsCerebral diffusion-weighted magnetic resonance imagingCerebral ischemic lesionsDays post procedurePrimary safety endpointDiffusion-weighted magnetic resonance imagingMajor cerebral arteriesTotal lesion volumeMagnetic resonance imagingSafety endpointIschemic lesionsTAVR proceduresCerebral arteryCerebral circulationConsecutive subjectsPost procedureAortic archHistorical controlsLesion volumeResonance imagingDW-MRIPatients
2011
DE NOVO CORONARY LESIONS TREATED WITH THE NOVEL POLYMER-FREE BIOLIMUS-A9 COATED STENTS: 12-MONTH ANGIOGRAPHIC RESULTS FROM THE PROSPECTIVE RANDOMIZED MULTICENTER BIOFREEDOM CLINICAL TRIAL
Costa R, Abizaid A, Mehran R, Magalhaes M, Gambone L, Parise H, Silva E, Schuler G, Hauptmann K, Schofer J, Grube E. DE NOVO CORONARY LESIONS TREATED WITH THE NOVEL POLYMER-FREE BIOLIMUS-A9 COATED STENTS: 12-MONTH ANGIOGRAPHIC RESULTS FROM THE PROSPECTIVE RANDOMIZED MULTICENTER BIOFREEDOM CLINICAL TRIAL. Journal Of The American College Of Cardiology 2011, 57: e1645. DOI: 10.1016/s0735-1097(11)61645-8.Peer-Reviewed Original ResearchCitations
2010
PRELIMINARY ANGIOGRAPHIC RESULTS OF THE NOVEL POLYMER-FREE BIOLIMUS-A9 COATED STENTS FOR THE TREATMENT OF CORONARY ARTERY LESIONS - FOUR-MONTH ANGIOGRAPHIC FOLLOW-UP OF THE PROSPECTIVE, RANDOMIZED, MULTICENTER BIOFREEDOM TRIAL
Costa R, Abizaid A, Mehran R, Lansky A, Magalhaes M, Gambone L, Parise H, Schuler G, Hauptmann K, Schofer J, Grube E. PRELIMINARY ANGIOGRAPHIC RESULTS OF THE NOVEL POLYMER-FREE BIOLIMUS-A9 COATED STENTS FOR THE TREATMENT OF CORONARY ARTERY LESIONS - FOUR-MONTH ANGIOGRAPHIC FOLLOW-UP OF THE PROSPECTIVE, RANDOMIZED, MULTICENTER BIOFREEDOM TRIAL. Journal Of The American College Of Cardiology 2010, 55: a192.e1801. DOI: 10.1016/s0735-1097(10)61802-5.Peer-Reviewed Original ResearchIMPACT OF ANEMIA IN MEN AND WOMEN WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: THE HORIZONS-AMI TRIAL
Tsujita K, Nikolsky E, Lansky A, Gambone L, Vandertie L, Caixeta A, Dangas G, Brodie B, Dudek D, Möckel M, Ochala A, Mehran R, Stone G. IMPACT OF ANEMIA IN MEN AND WOMEN WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2010, 55: a138.e1299. DOI: 10.1016/s0735-1097(10)61300-9.Peer-Reviewed Original ResearchIMPACT OF INTRAVENOUS HEPARIN ADMINISTERED PRIOR TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION: ANALYSIS FROM THE HORIZONS-AMI TRIAL
Nikolsky E, Mehran R, Dangas G, Lansky A, Rabbani L, Guagliumi G, Kornowski R, Hartmann F, Fahy M, Witzenbichler B, Peruga J, Gambone L, Parise H, Stone G. IMPACT OF INTRAVENOUS HEPARIN ADMINISTERED PRIOR TO PRIMARY PERCUTANEOUS CORONARY INTERVENTION: ANALYSIS FROM THE HORIZONS-AMI TRIAL. Journal Of The American College Of Cardiology 2010, 55: a185.e1729. DOI: 10.1016/s0735-1097(10)61730-5.Peer-Reviewed Original Research
2009
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, Investigators F. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. The Lancet 2009, 374: 1149-1159. PMID: 19717185, DOI: 10.1016/s0140-6736(09)61484-7.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryAnticoagulantsFemaleFollow-Up StudiesHemorrhageHeparinHirudinsHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexProportional Hazards ModelsRecombinant ProteinsStentsSurvival RateThrombosisTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionNet adverse clinical eventsPercutaneous coronary interventionAdverse clinical eventsBivalirudin groupMajor bleedingClinical eventsControl groupMyocardial infarctionAcute ST-segment elevation myocardial infarctionIIb/IIIa inhibitorsPrimary percutaneous coronary interventionHORIZONS-AMI trialMajor haemorrhagic complicationsPrimary trial endpointRate of MACERate of NACEElevation myocardial infarctionOnset of symptomsAcute myocardial infarctionOptimum treatment strategyWithdrawal of consentThrombin inhibitor bivalirudinImportant clinical implications